TITOLI ACCADEMICI
INCARICHI DIDATTICI
PUBBLICAZIONI (ultimi 5 anni)
A Falco, P Piscitelli, D Vito, F Pacella, C Franco, M Pulimeno, P Ambrosino, J Arias, A Miani (2023). COVID-19 epidemic spread and green areas Italy and Spain between 2020 and 2021: An observational multi-country retrospective study. Environ Res 216(Pt 1):114089.
Ambrosino P, Ragona F, Mosca I, Vannicola C, Canafoglia L, Solazzi R, Rivolta I, Freri E, Granata T, Messina G, Castellotti B, Gellera C, Soldovieri MV, DiFrancesco JC, Taglialatela M (2023). A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetine. Epilepsia. J64(7): e148-e155.
MC Cioclu, I Mosca, P Ambrosino, D Puzo, A Bayat, SB Wortmann, J Koch, V Strehlow, K Shirai, N Matsumoto, SJ Sanders, V Michaud, M Legendre, A Riva, P Striano, H Muhle, M Pendziwiat, G Lesca, GD Mangano, RNardello; KCNT2-study group; JR Lemke, RS Møller, MV Soldovieri, G Rubboli, M Taglialatela (2023). KCNT2-related disorders: phenotypes, functional and pharmacological properties. Ann Neurol 94(2):332-349.
Miceli F, Millevert C, Soldovieri MV, Mosca I, Ambrosino P, Carotenuto L, Schrader D, Lee HK, Riviello J, Hong W, Risen S, Emrick L, Amin H, Ville D, Edery P, de Bellescize J, Michaud V, Van-Gils J, Goizet C, Willemsen MH, Kleefstra T, Møller RS, Bayat A, Devinsky O, Sands T, Korenke GC, Kluger G, Mefford HC, Brilstra E, Lesca G, Milh M, Cooper EC, Taglialatela M, Weckhuysen S (2022). KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. EBioMedicine 81:104130.
Mosca I, Rivolta I, Labalme A, Ambrosino P, Castellotti B, Gellera C, Granata T, Freri E, Binda A, Lesca G, DiFrancesco JC, Soldovieri MV, Taglialatela M (2022). Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes. Front Pharmacol 13:872645.
Nappi M, Barrese V, Carotenuto L, Lesca G, Labalme A, Ville D, Smol T, Rama M, Dieux-Coeslier A, Rivier-Ringenbach C, Soldovieri MV, Ambrosino P, Mosca I, Pusch M, Miceli F, Taglialatela M (2022). Gain of function due to increased opening probability by two KCNQ5 pore variants causing developmental and epileptic encephalopathy. Proc Natl Acad Sci U S A 119(15):e2116887119.
Paventi G, Soldovieri MV, Servettini I, Barrese V, Miceli F, Sisalli MJ, Ambrosino P, Mosca I, Vinciguerra I, Testai L, Scorziello A, Raimo G, Calderone V, Passarella S, Taglialatela M (2022). Kv7.4 channels regulate potassium permeability in neuronal mitochondria. Biochem Pharmacol 197:114931.
Toraldo DM, Satriano F, Rollo R, Verdastro G, Imbriani G, Rizzo E, Argentiero A, Falco A, Ambrosino P, Miani A, Piscitelli P (2022). COVID-19 IgG/IgM patterns, early IL-6 elevation and long-term radiological sequelae in 75 patients hospitalized due to interstitial pneumonia followed up from 3 to 12 months. PLoS One 17(2):e0262911.
Alaimo A, Lorenzoni M, Ambrosino P, Bertossi A, Bisio A, Macchia A, Zoni E, Genovesi S, Cambuli F, Foletto V, De Felice D, Soldovieri MV, Mosca I, Gandolfi F, Brunelli M, Petris G, Cereseto A, Villarroel A, Thalmann G, Carbone FG, Kruithof-de Julio M, Barbareschi M, Romanel A, Taglialatela M, Lunardi A (2020). Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors. Cell Death Dis. 11(12):1039.
Soldovieri MV, Freri E, Ambrosino P, Rivolta I, Mosca I, Binda A, Murano C, Ragona F, Canafoglia L, Vannicola C, Solazzi R, Granata T, Castellotti B, Messina G, Gellera C, Labalme A, Lesca G, DiFrancesco JC, Taglialatela M (2020). Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy. Pharmacol Res 160:105200.
Ostacolo C, Miceli F, Di Sarno V, Nappi P, Iraci N, Soldovieri MV, Ciaglia T, Ambrosino P, Vestuto V, Lauritano A, Musella S, Pepe G, Basilicata MG, Manfra M, Perinelli DR, Novellino E, Bertamino A, Gomez-Monterrey IM, Campiglia P, Taglialatela M (2020). Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators. J Med Chem 63(1): 163-185.
Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflugers Arch. 472(7):881-898.
Ambrosino P, Soldovieri MV, Di Zazzo E, Paventi G, Iannotti FA, Mosca I, Miceli F, Franco C, Canzoniero LMT, Taglialatela M. (2019). Activation of Kv7 Potassium Channels Inhibits Intracellular Ca2+ Increases Triggered By TRPV1-Mediated Pain-Inducing Stimuli in F11 Immortalized Sensory Neurons. Int J Mol Sci 20(18): E4322.
Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M (2019). A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy. Epilepsia Open 4(3): 464-475.
Soldovieri MV, Ambrosino P, Mosca I, Miceli F, Franco C, Canzoniero LMT, Kline-Fath B, Cooper EC, Venkatesan C and Taglialatela M (2019). Epileptic Encephalopathy In A Patient With A Novel Variant In The Kv7.2 S2 Transmembrane Segment: Clinical, Genetic, and Functional Features. Int J Mol Sci 20(14): E3382.